Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.

1. Safety Management Team
2. Investigational Medicinal Product
3. Safety Signal
4. Safety Data Exchange Agreement
5. Risk Management
6. Dear Investigator Letter
7. Risk Communication
8. Informed Consent
9. Interventional Study
10. Pharmacovigilance
11. Other Safety Issue
12. Product Recall
13. Organized Data Collection Program
14. Drug Abuse
15. Non-validated signal
16. Pharmacoepidemiology
17. Adverse Event (AE)
18. Reference Safety Information
19. Post-authorization Safety Study
20. Important Potential Risks
21. Overdose
22. Product Safety Strategy
23. Adverse Event Report Number
24. Developmental Risk Management Plan
25. Corrective and Preventive Action (CAPA)
26. Development International Birth Date
27. Signal Assessment
28. Business Continuity Plan
29. Local Safety Representative
30. EudraVigilance
31. Listedness/ expectedness
32. Health Authority
33. Individual Case Safety Report (ICSR)
34. Validated Signal
35. Serious Adverse Event
36. BeiGene Representative
37. Medical Review
38. Investigator’s Brochure
39. Clinical Study Number
40. Sponsor
41. Investigator
42. Observational study
43. Identified Risk
44. Urgent Safety Measure
45. Affiliate
46. Clinical Trial Application
47. Patient Safety
48. Clinical Development Program
49. Good Clinical Practice
50. Country Safety Lead/Manager
51. process excellence
52. Non-Interventional Study
53. Spontaneous (Unsolicited) report
54. Signal Validation
55. PV Agreement
56. Pharmacovigilance
57. Signal Detection
58. Safety Assessment Team
59. Unexpected Events
60. GVP Module I
61. Risk Management Plan
62. Company Core Data Sheet
63. background rates
64. Qualified Person for Pharmacovigilance
65. Clinical Study
66. Suspected Unexpected Serious Adverse Reaction (SUSAR)
67. Safety Information
68. Good Pharmacovigilance Practice
69. Solicited reports
70. Global Patient Safety
71. Council for International Organizations of Medical Sciences
72. Adverse Drug Reaction (ADR)
73. Medical Dictionary for Regulatory Activities (MedRA)
74. Healthcare Professional
75. Signal Management Process
76. Marketing Authorization Holder
77. Pharmacovigilance System Master File
78. Expectedness
79. Causality Assessment
80. Pharmacovigilance System
81. Signal Detection Plan
82. Special Situations
83. Off-label use
84. Company Core Safety Information
85. Quality Assurance
86. Company Safety Committee
87. Development Safety Update Report
88. Monitoring Plan
89. Global Safety Database
90. New Drug Application
91. Refuted Signal
92. Post-Marketing Surveillance
93. Chief Safety Officer
94. Labeled or unlabeled
95. Drug Product
96. Periodic Benefit-Risk Evaluation Report
97. Side effect
98. Quality Management System (QMS)
99. alliance management
100. Non-serious AESI
101. Benefit-risk analysis
102. Regulatory authority
103. Risk-Benefit Balance
104. Drug Substance
105. Medicines and Healthcare Regulatory Agency
106. Investigational New Drug Application
107. Individual Case Safety Report
108. Product
109. Adverse Event of Special Interest (AESI)
110. Literature Report
111. Data Lock Point
112. Business Partner
113. Institutional Review Board
114. Tolerability
115. World Health Organization
116. Signal Prioritization
117. Periodic Safety Update Report
118. Protocol
119. Clinical Trial
120. Product Quality Complaint
121. Aggregate Safety Report (ASR)
122. periodic safety update report (PSUR)
123. Drug Adverse Event Reporting System
124. Subject Matter Expert
125. National Medical Product Administration
126. International Conference on Harmonization (ICH)
127. Blinding or Masking
128. Comparator Product
129. Occupational exposure
130. Contract Research Organization (CRO)